Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares S&P GSCI Commodity-Indexed Trust ETF vs Natera Inc. Common Stock — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $36.59 (market cap $1.04B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 54.8× iShares S&P GSCI Commodity-Indexed Trust ETF's market cap, and iShares S&P GSCI Commodity-Indexed Trust ETF is more actively traded (1,727,795 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold iShares S&P GSCI Commodity-Indexed Trust ETF for 40 Days and Natera Inc. Common Stock for 0 Days on average.
| GSG | NTRA | |
|---|---|---|
Market Cap | $1.04B | $57.03B |
Volume | 1,727,795 | 1,131,157 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.15 | $425.64 |
52-Week Low | $22.48 | $179.42 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSG trades at $36.77, up 0.96% with strong bullish technical signals from moving averages. The ETF shows volatile fundamentals with 2024 revenue of $51.25M and net income of $69.99M, though historical trends reveal significant profit margin swings from -126.61% in 2023 to 136.56% in 2024. Recent media coverage highlights commodity-focused positioning with energy exposure driving performance.
Outlook remains cautiously optimistic given bullish technical indicators and commodity market strength, but investors face volatility risks from energy sector exposure and geopolitical factors. The ETF's performance is heavily tied to broader commodity cycles, requiring careful monitoring of energy markets and global economic conditions.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
